
|Articles|November 15, 2007
First-line treatment for neovascular AMD
Combination therapy using photodynamic therapy and verteporfin (Visudyne, Novartis) as well as bevacizumab (Avastin, Genentech) can be effective in patients with age-related macular degeneration (AMD), particularly when patients are naïve to treatment, according to results from a patient registry.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
FDA approves NDA labeling supplement allowing re-administration of iDose TR
4
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain
5



























